Plowey, Edward D. http://orcid.org/0000-0001-9016-4751
Bussiere, Thierry
Rajagovindan, Raj
Sebalusky, Jennifer
Hamann, Stefan
von Hehn, Christian
Castrillo-Viguera, Carmen
Sandrock, Alfred
Budd Haeberlein, Samantha
van Dyck, Christopher H.
Huttner, Anita
Funding for this research was provided by:
National Institute on Aging (P30-AG066508, P50-AG047270-01)
Article History
Received: 27 January 2022
Revised: 5 May 2022
Accepted: 5 May 2022
First Online: 17 May 2022
Declarations
:
: Edward D. Plowey is an employee and shareholder of Biogen. Thierry Bussiere is an employee and shareholder of Biogen. Jennifer Sebalusky is an employee and shareholder of Biogen. Stefan Hamann is an employee and shareholder of Biogen. Carmen Castrillo-Viguera is an employee and shareholder of Biogen. Samantha Budd Haeberlein is an employee and shareholder of Biogen. Raj Rajagovindan was an employee of Biogen when this work was conducted, is a shareholder of Biogen and is currently an employee of Vigil. Christian von Hehn was an employee of Biogen when this work was conducted. Christian von Hehn is not a shareholder of Biogen. Alfred Sandrock was an employee of Biogen when this work was conducted and is a shareholder of Biogen. Christopher H. van Dyck was a PRIME and EMERGE trial site investigator. He is a consultant for Roche, Eisai, Ono, and Cerevel and receives research support from Biogen, Eisai, Roche, Genentech, Eli Lilly, Janssen, Merck, Novartis, and Biohaven. Anita Huttner has no competing interests to declare.
: Autopsy authorization, consent to utilize tissues for research and consent to publish was obtained according to Connecticut state law and approved protocols of the Yale University BioBank. The research study was approved by the Yale Alzheimer Disease Research Center (ADRC) and was reviewed and deemed exempt by the Yale University Institutional Review Board. The BioBank protocols are in accordance with the ethical standards of Yale University. Clinical and radiologic data were collected per the 221AD103 Study Protocol as previously published [CitationRef removed]. The Phase 1b PRIME study consent included permission to publish clinical data in the context of future research studies.